Literature DB >> 31658877

How oncogenic mutations activate human MAP kinase 1 (MEK1): a molecular dynamics simulation study.

Ye Liu1, Jingxuan Zhu1, Xiaoqing Guo1, Tianci Huang1, Jiarui Han1, Jianjiong Gao2, Dong Xu3,4, Weiwei Han1.   

Abstract

Approximately 30% of all types of human cancers possess a constitutively activated the mitogen-activated protein kinase (MAPK) signaling pathway while MAP kinase 1 (MEK1) is a critical component of this pathway. It has been reported mutations could improve the activity of MEK1 to result in cell proliferation and transformation, which is a known oncogenic event in various cancer types. In this study, eight molecular dynamics simulations, molecular mechanics Poisson-Boltzmann surface area (MM-PBSA), combined with protein structure network were performed to explore the mechanism that mutations activate MEK1. Protein structure networks and hydrogen bonds analysis demonstrated that active mutations broke the interaction between activation segments (residues 216-222) and C-helix (residues 105-121) in MEK1, leading to it transform inactive form to active form. Moreover, hydrogen bond analysis and MM-PBSA calculation indicated that activating mutations decrease the binding affinity between MEK1 and inhibitor to reduce the inhibitory effect of inhibitors. In addition, some active mutations cause structural changes in the Pro-rich loop (residues 261-268) of MEK1. These changes may stabilize the interaction between the MEK1 mutants and the ligands by increasing the number of exposed hydrophobic residues in the active site of MEK1. Our results may provide useful theoretical evidences for the mechanism underlying the role of human MEK1 in human cancers.Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  MAP kinase 1 (MEK1); MAPK pathway; MM-PBSA; cancer; conformational change; molecular dynamics simulation

Mesh:

Substances:

Year:  2019        PMID: 31658877      PMCID: PMC8177546          DOI: 10.1080/07391102.2019.1686065

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  47 in total

Review 1.  Coordinating ERK/MAPK signalling through scaffolds and inhibitors.

Authors:  Walter Kolch
Journal:  Nat Rev Mol Cell Biol       Date:  2005-11       Impact factor: 94.444

2.  Hydration thermodynamic properties of amino acid analogues: a systematic comparison of biomolecular force fields and water models.

Authors:  Berk Hess; Nico F A van der Vegt
Journal:  J Phys Chem B       Date:  2006-09-07       Impact factor: 2.991

3.  Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors.

Authors:  Thierry O Fischmann; Catherine K Smith; Todd W Mayhood; Joseph E Myers; Paul Reichert; Anthony Mannarino; Donna Carr; Hugh Zhu; Jesse Wong; Rong-Sheng Yang; Hung V Le; Vincent S Madison
Journal:  Biochemistry       Date:  2009-03-31       Impact factor: 3.162

Review 4.  RAF protein-serine/threonine kinases: structure and regulation.

Authors:  Robert Roskoski
Journal:  Biochem Biophys Res Commun       Date:  2010-07-30       Impact factor: 3.575

Review 5.  The ERK/MAPK pathway, as a target for the treatment of neuropathic pain.

Authors:  Weiya Ma; Remi Quirion
Journal:  Expert Opin Ther Targets       Date:  2005-08       Impact factor: 6.902

6.  A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.

Authors:  Damian F Brennan; Arvin C Dar; Nicholas T Hertz; William C H Chao; Alma L Burlingame; Kevan M Shokat; David Barford
Journal:  Nature       Date:  2011-03-27       Impact factor: 49.962

7.  Dynamical networks in tRNA:protein complexes.

Authors:  Anurag Sethi; John Eargle; Alexis A Black; Zaida Luthey-Schulten
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-07       Impact factor: 11.205

8.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Authors:  Keiran S M Smalley; Mercedes Lioni; Maurizia Dalla Palma; Min Xiao; Brijal Desai; Suzanne Egyhazi; Johan Hansson; Hong Wu; Alastair J King; Patricia Van Belle; David E Elder; Keith T Flaherty; Meenhard Herlyn; Katherine L Nathanson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

9.  Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.

Authors:  D R Knighton; J H Zheng; L F Ten Eyck; V A Ashford; N H Xuong; S S Taylor; J M Sowadski
Journal:  Science       Date:  1991-07-26       Impact factor: 47.728

10.  3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets.

Authors:  Jianjiong Gao; Matthew T Chang; Hannah C Johnsen; Sizhi Paul Gao; Brooke E Sylvester; Selcuk Onur Sumer; Hongxin Zhang; David B Solit; Barry S Taylor; Nikolaus Schultz; Chris Sander
Journal:  Genome Med       Date:  2017-01-23       Impact factor: 11.117

View more
  2 in total

1.  Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.

Authors:  Aphrothiti J Hanrahan; Brooke E Sylvester; Matthew T Chang; Arijh Elzein; Jianjiong Gao; Weiwei Han; Ye Liu; Dong Xu; Sizhi P Gao; Alexander N Gorelick; Alexis M Jones; Amber J Kiliti; Moriah H Nissan; Clare A Nimura; Abigail N Poteshman; Zhan Yao; Yijun Gao; Wenhuo Hu; Hannah C Wise; Elena I Gavrila; Alexander N Shoushtari; Shakuntala Tiwari; Agnes Viale; Omar Abdel-Wahab; Taha Merghoub; Michael F Berger; Neal Rosen; Barry S Taylor; David B Solit
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

2.  Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors.

Authors:  Siao Chen; Yi He; Yajiao Geng; Zhi Wang; Lu Han; Weiwei Han
Journal:  Molecules       Date:  2021-12-26       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.